2.2.0.25falsefalse10801 - Disclosure - Acquisitiontruefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010 USD ($) USD ($) / shares $Duration_1_1_2010_To_12_31_2010http://www.sec.gov/CIK0000024741duration2010-01-01T00:00:002010-12-31T00:00:00Unit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit14Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0Unit1Standardhttp://www.xbrl.org/2003/instancesharesxbrli0Unit13Standardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$2true0glw_AcquisitionAbstractglwfalsenadurationAcquisition [Abstract]falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringAcquisition [Abstract]falsefalseAcquisition3false0us-gaap_BusinessCombinationDisclosureTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00<div> 8.     Acquisition   On September 15, 2009, Corning acquired all of the shares of Axygen Bioscience, Inc. and its subsidiaries (Axygen) from American Capital Ltd. for $410 million, net of $7 million cash received.  Axygen is a leading manufacturer and distributor of high-quality life sciences plastic consumable labware, liquid handling products, and bench-top laboratory equipment.   The purchase price of the acquisition was allocated to the net tangible and other intangible assets acquired, with the remainder recorded as goodwill on the basis of fair value.  The following amounts represent the final valuation of the acquisition (in millions): <table style="border-collapse: collapse; font-family: 'Times New Roman','serif'; margin-left: 5.4pt; font-size: 10pt;" class="MsoNormalTable" border="0" cellspacing="0" cellpadding="0"> <tr><td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 488.35pt; padding-right: 5.4pt; border-top: windowtext 2.25pt solid; border-right: medium none; padding-top: 0in;" valign="bottom" width="651"> Total current assets</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 15.8pt; padding-right: 5.4pt; border-top: windowtext 2.25pt solid; border-right: medium none; padding-top: 0in;" valign="bottom" width="21"> $</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 26.85pt; padding-right: 5.4pt; border-top: windowtext 2.25pt solid; border-right: medium none; padding-top: 0in;" valign="bottom" width="36"> 63</td></tr> <tr><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 488.35pt; padding-right: 5.4pt; padding-top: 0in;" valign="bottom" width="651"> Other tangible assets</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 15.8pt; padding-right: 5.4pt; padding-top: 0in;" valign="bottom" width="21">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 26.85pt; padding-right: 5.4pt; padding-top: 0in;" valign="bottom" width="36"> 49</td></tr> <tr><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 488.35pt; padding-right: 5.4pt; padding-top: 0in;" valign="bottom" width="651"> Other intangible assets</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 15.8pt; padding-right: 5.4pt; padding-top: 0in;" valign="bottom" width="21">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 26.85pt; padding-right: 5.4pt; padding-top: 0in;" valign="bottom" width="36"> 153</td></tr> <tr><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 488.35pt; padding-right: 5.4pt; padding-top: 0in;" valign="bottom" width="651"> Current and non-current liabilities</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 15.8pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="21">  </td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 26.85pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="36"> (80)</td></tr> <tr><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 488.35pt; padding-right: 5.4pt; padding-top: 0in;" valign="bottom" width="651"> Net tangible and intangible assets</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 15.8pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="21"> $</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 26.85pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="36"> 185</td></tr> <tr><td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 488.35pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="651"> Purchase price, including cash received</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 15.8pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="21">  </td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 26.85pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="36"> 417</td></tr> <tr><td style="border-bottom: windowtext 2.25pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 488.35pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="651"> Goodwill (1)</td> <td style="border-bottom: windowtext 2.25pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 15.8pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="21"> $</td> <td style="border-bottom: windowtext 2.25pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 26.85pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="36"> 232</td></tr></table>   <div> (1)   None of the goodwill recognized is deductible for U.S. income tax purposes.  The goodwill was allocated to the Life Sciences segment.</div>   Goodwill is primarily related to the value of Axygen's product portfolio and distribution network and its combination with Corning's existing life sciences platform, as well as synergies and other intangibles that do not qualify for separate recognition.  Acquisition-related costs of $4 million in 2009 included costs for legal, accounting, valuation and other professional services and were included in selling, general and administrative expense in the Consolidated Statements of Income.  Supplemental pro forma information was not provided because Axygen is not material to Corning's consolidated financial statements. </div>8.     Acquisition   On September 15, 2009, Corning acquired all of the shares of Axygen Bioscience, Inc. and its subsidiariesfalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringDescription of a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. This element may be used as a single block of text to encapsulate the entire disclosure (including data and tables) regarding business combinations, including leverage buyout transactions (as applicable).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 51, 52 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 88-16 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141R -Paragraph 67-73 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141R -Paragraph F4 -Subparagraph e -Appendix F falsefalseAcquisition12AcquisitionUnKnownUnKnownUnKnownUnKnownfalsetrue